---
layout: post
title: "Patient-Focused Drug Development for Long COVID; Public Meeting; Request for Comments"
date: 2026-02-05 18:35:41 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-03714
original_published: 2023-02-23 00:00:00 +0000
significance: 8.00
---

# Patient-Focused Drug Development for Long COVID; Public Meeting; Request for Comments

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** February 23, 2023 00:00 UTC
**Document Number:** 2023-03714

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Long COVID." The purpose of the public meeting is to allow FDA to obtain patient perspectives on the impact of Long COVID on daily life, patient views on treatment approaches, and decision factors considered when selecting a treatment.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/02/23/2023-03714/patient-focused-drug-development-for-long-covid-public-meeting-request-for-comments)
- API: https://www.federalregister.gov/api/v1/documents/2023-03714

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
